AScribe Health News Service - New Study Examines SEROQUEL Treatment for Depressive Episodes Associated With Bipolar Disorder; In First Large-Scale SEROQUEL Study Including Both Bipolar I,…
Byline: Edelman Public Relations
Related Results
New SeroquelSeroquel indicationSeroquel Backgrounder.Seroquel approvedAZ’s Seroquel faces competition
WILMINGTON, Del., May 5 (AScribe Newswire) — AstraZeneca (NYSE: AZN) today announced results from the first large-scale study that examined SEROQUEL(r) (quetiapine fumarate) as a treatment for depressive episodes that included both patients with bipolar I and II disorders. Results from this clinical trial suggest improvement in depressive symptoms for those taking SEROQUEL. Depressive episodes are characterized by prolonged periods of sadness, unexplained loss of energy, persistent lethargy and recurring thoughts of death or suicide. SEROQUEL is a …
Read the rest of this article with a Free Trial at HighBeam Research.
